Ray Dalio Halozyme Therapeutics, Inc. Transaction History
Bridgewater Associates, LP
- $17.3 Billion
- Q3 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 11,515 shares of HALO stock, worth $552,604. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,515
Previous 33,221
65.34%
Holding current value
$552,604
Previous $1.74 Million
62.16%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$846 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$619 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$318 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$195 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$164 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.68B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...